Tradestie Institutional Equity Comparison Engine

CRSP vs FDMT โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

FDMT Overall Edge

FDMT Captures Institutional Edge (3โ€“1 Pillars ยท 4โ€“6 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to 4D Molecular Therapeutics, Inc. Common Stock (FDMT) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while CRSP counters with relative strength in Valuation. Fundamentally, CRSP trades at 23.4x Forward P/E with -2058.6% operating margin (+1325.1% YoY revenue) versus FDMT at N/M Forward P/E and -222.7% operating margin (+4505.6% YoY). In options structure, CRSP sits in BREAKDOWN (52nd %ile IV; Dealer Gamma Walls on Pro) against FDMT sits in BREAKDOWN (10th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner CRSP
CRSP 23.4x vs FDMT N/M Fwd P/E
Growth & Margin Winner FDMT
Op Margin -2058.6% vs -222.7% ยท YoY +1325.1% vs +4505.6%
Momentum & Technical Winner FDMT
1Y -20.5% vs +13.3% ยท 52W Pos 1% vs 47%
Options & Structure Winner FDMT
BREAKDOWN (52nd %ile IV) vs BREAKDOWN (10th %ile IV)
CRSP NASDAQ
CRISPR Therapeutics AG
Biological Products, (No Disgnostic Substances)
$40.61
-3.86% 1D
Market Cap $4.1B
1M Return -17.54%
1Y Return -20.54%
Forward P/E 23.4x
Unified AI Score
44.7 / 100 HOLD
Tech 25.0 Fund 52.0 Flow 68.0 Mom 55.0
FDMT NASDAQ
4D Molecular Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$11.65
-4.74% 1D
Market Cap $669.3M
1M Return -4.04%
1Y Return +13.33%
Forward P/E N/M
Unified AI Score
51.3 / 100 HOLD
Tech 51.0 Fund 47.0 Flow 66.0 Mom 54.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: CRSP -20.54% FDMT +13.33% Spread: +33.87 pp (FDMT Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period CRSP Revenue FDMT Revenue CRSP Op. Margin FDMT Op. Margin Margin Edge
FY2018 $0M N/A -5087.8% N/A CRSP
FY2019 $290M $10M 16.1% -729.4% CRSP
FY2020 $0M $10M -49295.5% -424.0% FDMT
FY2021 $910M $20M 40.8% -395.5% CRSP
FY2022 $0M $0M -56190.4% -3516.5% FDMT
FY2023 $370M $20M -60.0% -544.6% CRSP
FY2024 $40M $0M -1250.4% -507678.4% CRSP
FY2025 $0M $90M -18933.6% -187.2% FDMT

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: CRSP (6) vs FDMT (4)
Institutional Metric CRSP FDMT Criterion Row Winner
Market Capitalization Scale $4.1B $669.3M Larger Scale CRSP
Trailing P/E Ratio Valuation 23.4x N/M Lower Multiple CRSP
Forward P/E Ratio Valuation 23.4x N/M Lower Multiple CRSP
Revenue Growth (YoY) Growth +1325.1% +4505.6% Higher Growth FDMT
Operating Margin (TTM) Profitability -2058.6% -222.7% Higher Margin FDMT
Net Profit Margin Profitability 0.0% -208.6% Higher Margin CRSP
Return on Equity (ROE) Capital Efficiency -25.6% -56.7% Higher ROE CRSP
52-Week Range Position Momentum 1% ($40โ€“$63) 47% ($7โ€“$17) Stronger Trend FDMT
Beta / 30D Volatility Risk Regime 1.85ฮฒ ยท 60% Vol 1.89ฮฒ ยท 90% Vol Lower Realized Risk CRSP
Unified Institutional Score Composite Signal 44.7 / 100 (HOLD) 51.3 / 100 (HOLD) Higher Composite FDMT

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full CRSP vs FDMT Buy Guide
CRSP BREAKDOWN
58d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 52nd %ile
IV Regime Balanced (25thโ€“60th %ile)
Live CRSP Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
FDMT BREAKDOWN
62d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 10th %ile
IV Regime Compressed (<25th %ile)
Live FDMT Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither CRSP nor FDMT registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.